Dupilumab
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Eczema
Conditions
Eczema, Atopic Dermatitis
Trial Timeline
Mar 1, 2022 → Mar 1, 2024
NCT ID
NCT05265234About Dupilumab
Dupilumab is a approved stage product being developed by Regeneron Pharmaceuticals for Eczema. The current trial status is unknown. This product is registered under clinical trial identifier NCT05265234. Target conditions include Eczema, Atopic Dermatitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06631677 | Pre-clinical | Completed |
| NCT04776694 | Pre-clinical | Completed |
| NCT06226610 | Phase 2 | Recruiting |
| NCT05042258 | Approved | Recruiting |
| NCT06012448 | Approved | Completed |
| NCT05720325 | Phase 2 | Recruiting |
| NCT05268107 | Approved | Recruiting |
| NCT05128383 | Phase 2 | Completed |
| NCT05265234 | Approved | UNKNOWN |
| NCT05036733 | Approved | Completed |
| NCT05246267 | Pre-clinical | Recruiting |
| NCT04148352 | Phase 2 | Terminated |
| NCT04296864 | Phase 2 | UNKNOWN |
| NCT03935971 | Approved | Active |
| NCT03886493 | Phase 2 | Terminated |
| NCT03667014 | Approved | Completed |
Competing Products
20 competing products in Eczema